Transition Bio is a dynamic, fast-growing company. Our team is busy working hard to change lives. When there is something to share, you’ll find it here.
Latest News
Transition Bio, Inc. and Voyager Therapeutics jointly announced a drug discovery collaboration targeting TDP-43 for ALS and FTD.
Transition Bio presented results from its lead small-molecule inhibitor program targeting YTHDC1 highlighting robust efficacy in MYC-driven cancers, both as a single agent and in combination with standard-of-care therapies.
Transition Bio, Inc., a microfluidics- driven drug discovery platform company using biophysical…
Transition Bio, Inc. (the Company) today named several critical additions to its leadership team, including naming Gregory Miller as CEO…
Transition Bio, Inc., (the Company) announced today that Dr. Sarah Teichmann FmedSci FRS, has joined.…
New research from the departments of chemistry and physics at Cambridge University has just helped demonstrate the potential of natural…
Transition Bio, Inc., announced today that Professor Peter St George-Hyslop, a world recognized pioneer…
Transition Bio, Inc., was recently formed, funded, and launched with the focused objective to build the best…
